The LUCENT-2 study (ClinicalTrials.gov Identifier: NCT03524092) is a maintenance study of mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). touchIMMUNOLOGY caught up with Prof. Marla C. Dubinsky (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to find out the efficacy and safety findings of the study and where mirikizamab would fit in the treatment paradigm for UC, if approved.
The abstract ‘EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY.‘ was presented at Digestive Disease Week 2022, May 21-24, 2022.
Questions
- What were the efficacy and safety findings of the study? (0:20)
- If approved, where do you see mirikizamab sitting in the expanding treatment paradigm for ulcerative colitis? (9:54)
Disclosures: Marla C. Dubinsky discloses consulting and serving on advisory boards for Lilly.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of DDW 2022.
